v3.25.4
Revenue from Contracts with Customers
 9 Months Ended
Jan. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Revenue
The following table represents disaggregated revenue for the three and nine months ended January 31, 2026 and 2025 (in thousands):
Three Months Ended
January 31,		Nine Months Ended January 31,
 2026202520262025
Pharmacology services$16,184 $11,670 $43,929 $37,237 
TOS data license revenue— 4,500 468 4,500 
Other TOS revenue375 869 1,193 2,852 
Total oncology revenue$16,559 $17,039 $45,590 $44,589 
Translational Oncology Solutions ("TOS") license revenue represents revenue from the sale of a license to access certain of the Company's PDX data. Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software ("Lumin").